Asset profile

atropine · Ligand (LGND)

Indication: slow progression of myopia in pediatric patients
Also known as: Ryjunea, low-dose atropine eye drop, 0.01% atropine

Company

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's busi…

Start live analysis of LGND Run 8-agent AI analysis

On the calendar

Sep 2026

Sep 25, 2026

27 days ago

LGNDLigand

Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%

Advisory committeeOutcome not recordedFederal Register

Nov 2026

~ Nov 2026

LGNDLigand

atropine: Phase 2 trial NCT07816224 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Dec 2026

Dec 31, 2026

in 70 days

LGNDLigand

atropine: Phase 3 trial NCT06708156 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

Oct 15, 2026

03:22 AM

LGNDLigand

atropine · NCT07816224 registry update

Trial registry changeClinicalTrials.gov Open record

Sep 25, 2026

12:00 AM

LGNDLigand

Advisory committee scheduledFederal Register Open record6 updates

Sep 22, 2026

11:08 AM

LGNDLigand

Ligand Acquires Royalty Interest in Santen's Ryjunea (atropine) from Sydnexis

Partnership / licensing dealSEC 8-K Open record

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Oct 15, 2026

Primary endpoint metUnknown

Overall survival significant or trendingUnknown

US / Western patient shareMixed

3 of 29 sites in the United States

Advisory committee scheduledMixed

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

Sydnexis Not US-listedPartner

Santen Not US-listedPartner

LGNDLigandOwner

SEC 8-K Sep 22, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT06708156	Phase 3	Recruiting	Dec 31, 2026	606	0 of 25 sites in the United States
NCT04391361	Phase 2	Unknown	Sep 30, 2023	30	0 of 1 sites in the United States
NCT06865677	Phase 2	Terminated	Jul 1, 2025	2	1 of 1 sites in the United States
NCT07816224	Phase 2	Recruiting	Nov 1, 2026	16	2 of 2 sites in the United States